1 Molecular epidemiology of carbapenem-resistant Enterobacter cloacae complex infections 2 uncovers high frequency of non-carbapenemase-producers in five tertiary care hospitals 3 from Colombia 4 5 16 2 17 Abstract. 18 Background. Infections caused by carbapenem-resistant Enterobacter cloacae (CR-Ecl) 19 have been increasingly reported in the clinical setting; here we describe the clinical and 20 molecular characteristics of CR-Ecl infections in a KPC endemic region. 21 Methods. A cross-sectional study was conducted in five tertiary-care hospitals in Medellín-22 Colombia. All patients infected by CR-Ecl from June-2012 to June-2014 were included. 23 Sociodemographics and clinical information was retrieved from medical records. 24 Antimicrobial susceptibility testing, phenotypic and molecular carbapenemase detection 25 were performed. Analysis of hsp60 and PFGE was done in a subset of isolates. 26 Results. Of 109 patients enrolled, 60.55% (66/109) were infected with non-carbapenemase-27 producing-Ecl (non-CP-Ecl). CP-Ecl patients were frequently hospitalized in the ICU 28 (37.21% vs 12.12%) and had exposure to carbapenems (39.53% vs 15.15%) compared to 29 non-CP-Ecl infected patients. All-cause 30-day mortality was higher in CP-Ecl than non-30 CP-Ecl infected patients (27.91% vs 19.70%). CP-Ecl harbored KPC-2 (83.72%) and KPC-31 3 (6.97%). Analysis of hsp60 showed that CP-Ecl belonged primarily to cluster-VI of 32 Enterobacter xiangfangensis (12/34) and cluster-XI (12/34) corresponding to E. cloacae 33 subsp. cloacae. Non-CP-Ecl isolates belonged to cluster-VII/VIII (45/54), of E. hormaechi 34 subsp. steigerwaltii. PFGE revealed isolates in cluster VII/VIII and XI were closely related 35 within their own clusters. 36 Conclusions: The results revealed a high frequency of non-CP-Ecl among the CR-Ecl 37 infections in a KPC endemic region, displaying distinct clinical and molecular 38 characteristics in comparison to CP-Ecl. The study highlights a significant contribution of 39 non-CP-Ecl to the prevalence of CR-Ecl. Infection control measures to curtail 3 40 dissemination of CR-Ecl should not only focus on CP-Ecl but should also include non-CP-41 Ecl. 42 43 Keywords: cross-sectional study, carbapenem-resistant, Enterobacter cloacae complex. 44 45 Introduction. 46 Enterobacter spp. have become a significant pathogen in clinical settings in the last decades 47 (1). In fact, Enterobacter cloacae is among the top-five bacteria causing intra-abdominal 48 infections in hospital and community settings in all regions of the world (2). Data from the 49 National Nosocomial Infections Surveillance (NNIS) System from 1986-2003 in United 50 States showed Enterobacter was a frequent cause of pneumonia (10.0%), bloodstream 51 (4.4%), surgical site (9.0%) and urinary tract infections (UTI) (6.9%) among Gram-52 negative bacilli (3) and it was mainly associated with infections occurring in intensive care 53 units (ICU) (4). Similarly, in Latin America, Enterobacter spp. is also among the top-five 54 Gram-negative pathogens causing bloodstream infections (4.5%), pneumonia (5.1%) and 55 skin and soft tissue infections (6.8%) (5). 56 57 Enterobacter spp. is increasingly associated with multi-drug resistance, including the 58 resistance to the "last-resort" carbapenems. Wilson et al. (6) recently described two 59 epidemics of carbapenem-resistant bacteria in United States. The first and most notorious 60 started in 2000 and it was caused by the expansion of KPC-K. pneumoniae from the east to 61 the pacific coast of the country, although resistance rates are decreasing in recent years. 62 The second is the unfolding epidemic caused by carbapenem-resistant E. cloacae (CR-Ecl) 63 extending from the east to the southwest and pacific coast of United States; in contrast to K. 4 64 pneumoniae, rates of carbapenem resistance appear to be growing in E. cloacae in recent 65 years. Additionally, multiple outbreaks of CR-Ecl harboring KPC (7,8), VIM (9), IMP (10) 66 and OXA-48 (11) carbapenemases have been reported globally, highlighting the key role of 67 Enterobacter in dissemination of carbapenem resistance. 68 69 In Colombia, E. cloacae is reported to be one of the most commonly isolated pathogens in 70 both ICU and non-ICU wards (12). More alarmingly, the national surveillance data also 71 showed that carbapenem-resistance rates in E. cloacae (10-16%) are similar to K. 72 pneumoniae (14-15%) (12). However, KPC carbapenemases were only detected in 66% of 73 E. cloacae isolates from the national program on antimicrobial resistance during 2012 to 74 2015, suggesting additional mechanisms mediating carbapenem-resistance in CR-Ecl (13). 75 Despite the clinical importance of this pathogen, only a few studies have focused on the 76 characterization of infections caused by CR-Ecl. The aim of this study is to describe the 77 clinical and microbiological characteristics of infections caused by CR-Ecl in a KPC 78 endemic region. 79 80 Materials and Methods. 81 82 Study design and setting. A cross-sectional study was conducted in the city of Medellin, 83 the second largest city in Colombia with 2.5 million inhabitants. The study was conducted 84 in five tertiary care hospitals capturing both adult and pediatric populations. Hospital A 85 (700-beds) and Hospital C (754-beds) are large university hospitals, Hospital B (286-beds) 86 and Hospital D (300-beds) are medium size tertiary care centers and Hospital E (140-beds) 87 is a small hospital specialized in cardiovascular diseases. 5 88 89 Participants. All patients infected with carbapenem-resistant Enterobacter cloacae 90 complex isolates in the five tertiary care hospitals from June 2012 to June 2014 were 91 enrolled. Patients from any age, service and type of infection were included in the study at 92 the time of the first CR-Ecl infection. Specialists in infectious diseases established the 93 infection/colonization status of the patients using previous standardized definitions (14). 94 The study protocol was approved by the Committee of Bioethics for Human Research at the 95 Universidad de Antioquia (CBE-SIU) (approval no. 11-35-415) and by the Committee of 96 Ethics at each of the participant institutions. 97 98 Clinical information. Information retrieved from the medical records included 99 sociodemographics (age and sex) and the following clinical variables: time at risk (defined 100 as the number of days from admission to the date of sampling), transfer from another 101 facility, ICU stay, use of invasive devices at the time of sampling or 48 hours before 102 sampling, previous healthcare exposures (surgery in the previous year, prior ICU stay and 103 antibiotic use in the last six months), dialysis, neutropenia, immunosuppressive conditions, 104 comorbidities (trauma, cancer, diabetes mellitus, cystic fibrosis, neurological disease, 105 cardiovascular disease, lung disease, burns, transplant, chronic obstructive disease), health 106 care associated infection, mixed infection, empirical and targeted treatment, discharge 107 (death, clinical improvement, cure). All clinical information was retrieved from the medical 108 records and included in a standardized formulary by specialists in infectious diseases at 109 each institution. 110 Microbial identification and antimicrobial susceptibility testing. Identification of 111 isolates and antimicrobial susceptibility testing was carried out by the Vitek® 2 automated 6 112 system (bioMérieux, Marcy l'Etoile, France). Antibiotics tested included ceftriaxone, 113 ceftazidime, cefepime, ertapenem, imipenem, meropenem, ciprofloxacin, gentamicin, 114 amikacin, tigecycline and colistin. Resistant, intermediate or susceptible categories were 115 defined following CLSI guidelines (15). Isolates were considered resistant to carbapenems 116 if at least one of the carbapenems was non-susceptible (imipenem, meropenem or 117 doripenem MIC ≥ 2 µg/mL or ertapenem MIC ≥ 1 µg/mL) (15). 118 119 Phenotypic and molecular detection of β-lactamases. The three-dimensional test, which 120 uses a mechanical lysate of the tested isolate to increase the sensitivity of carbapenemase 121 detection (16), was performed in all CR-Ecl isolates. In addition, modified Hodge Test 122 (MHT) (15) was conducted in a subset of 65 isolates. Molecular detection of bla KPC 123 variants were done using a molecular beacon-based real-time PCR assay (17). Isoforms of 124 Tn4401 element were evaluated by PCR (18). Detection of additional carbapenemase genes 125 bla VIM , bla IMP, bla NDM and bla OXA-48 were done by conventional multiplex PCR (19). In 126 addition, extended spectrum β-lactamases (ESBLs) genes bla CTX-M-1 , bla CTX-M-2 , bla CTX-M-127 8 , bla CTX-M-9 , bla CTX-M-25 , bla TEM and bla SHV were evaluated using PCR and Sanger 128 sequencing (20), and acquired AmpC genes bla ACT/MIR , bla CMY-1/MOX , bla CMY-2/LAT , bla FOX , 129 bla DHA and bla ACC were assessed using PCR (20). 130 131 Sequence analysis of ompF. To investigate additional mechanisms related to carbapenem 132 resistance in E. cloacae isolates, the full-length sequences of ompF were analyzed in a 133 subset of 91 isolates. Sequences were compared to the reference strain E. cloacae NCTC
). (Figure 2 and 3) . The majority of isolates from cluster VII/VIII were recovered 279 spanning the two-year study period ( Figure S2 ). Isolates from this cluster were found in a 280 variety of infections ( Figure S1 ). 
